CEO Buys $25,000 in Bluejay Diagnostics via Private Placement
BJDX is trading near its 52-week low of $1.63 (9.8% above the low) on light trading volume (0.2× avg).
Summary
Bluejay Diagnostics' CEO invested $25,000 in the company through a private placement, demonstrating conviction despite the company's going concern warning and paying a premium to the current stock price.
Key Events · Ownership and Investor Activity · BJDX
-
CEO Stock Purchase
Indranil Dey, President and CEO, acquired 12,500 shares for $25,000 in a private placement on March 14, 2026.
-
Premium Purchase Price
The shares were purchased at $2.00 each, which is above the current market price of $1.79.
-
Significant Relative Investment
This purchase represents 1.4% of the company's market capitalization, a substantial investment for a micro-cap company facing a going concern warning.
Analysis · BJDX · Industrial Applications And Services
Bluejay Diagnostics' CEO, Indranil Dey, purchased $25,000 worth of common stock in a private placement at $2.00 per share. This transaction represents a significant personal investment relative to the company's small market capitalization (1.4% of market cap) and occurs while the company faces a critical going concern warning. The purchase price is also at a premium to the current market price of $1.79, indicating strong conviction from the CEO amidst financial challenges.
At the time of this filing, BJDX was trading at $1.79 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.63 to $16.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.